Janus kinase inhibitors in dermatology: Part I. A comprehensive review.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 34246698.
- Also identified by DOI 10.1016/j.jaad.2021.07.002.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The Janus kinase-signal transducer and activator of transcription (JAK-STAT) intracellular signaling pathway is utilized by many proinflammatory molecules to mediate downstream effects and activate gene transcription. Activation of the JAK-STAT pathway contributes to a number of inflammatory dermatoses. Clinical trials and smaller studies have demonstrated the efficacy of JAK inhibitors in the treatment of a variety of dermatologic conditions. Here, we review the use of JAK inhibitors for the treatment of a wide range of dermatologic diseases in a two-part review series.
Medical subject headings
- Dermatology
- Janus Kinase Inhibitors